An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo + trastuzumab ± pembro in first-line metastatic HER2+ gastric or gastroesophageal junction (GEJ) cancer: DESTINY-Gastric05.

Authors: Kohei Shitara, Lin Shen, Jeeyun Lee, Paulo Marcelo Hoff, Elizabeth Catherine Smyth, Daniel Barrios, Kojiro Kobayashi, Yasuyuki Okuda, Takahiro Kamio, Yelena Y. Janjigian

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4207

Source: Full article

---

Abstract

TPS4207